Deep-pocketed investors have adopted a bullish approach towards Intellia Therapeutics NTLA, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NTLA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Intellia Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 25% bearish. Among these notable options, 6 are puts, totaling $328,340, and 6 are calls, amounting to $448,473.
Expected Price Movements
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $25.0 for Intellia Therapeutics over the recent three months.
Volume & Open Interest Trends
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intellia Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intellia Therapeutics's substantial trades, within a strike price spectrum from $25.0 to $25.0 over the preceding 30 days.
Intellia Therapeutics Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTLA | CALL | SWEEP | BULLISH | 01/17/25 | $5.1 | $5.0 | $5.1 | $25.00 | $117.3K | 1.6K | 145 |
| NTLA | CALL | SWEEP | BULLISH | 01/17/25 | $4.9 | $4.7 | $4.9 | $25.00 | $113.1K | 1.6K | 526 |
| NTLA | PUT | SWEEP | BEARISH | 01/17/25 | $5.3 | $4.8 | $5.3 | $25.00 | $94.8K | 2.3K | 340 |
| NTLA | CALL | SWEEP | BULLISH | 01/17/25 | $5.0 | $4.5 | $5.0 | $25.00 | $75.5K | 1.6K | 375 |
| NTLA | PUT | SWEEP | BULLISH | 01/17/25 | $5.5 | $5.3 | $5.3 | $25.00 | $66.7K | 2.3K | 519 |
About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Present Market Standing of Intellia Therapeutics
- Trading volume stands at 742,147, with NTLA's price down by -0.65%, positioned at $24.64.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 42 days.
What The Experts Say On Intellia Therapeutics
In the last month, 2 experts released ratings on this stock with an average target price of $65.0.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $65.
- Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $65.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intellia Therapeutics with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
